Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 53Leukemia, Myeloid, Acute 52Neoplasm Metastasis 45Carcinoma, Non-Small-Cell Lung 40Prostatic Neoplasms 37Breast Neoplasms 36Multiple Myeloma 31Colorectal Neoplasms 29Pancreatic Neoplasms 26Carcinoma, Renal Cell 25Melanoma 23Ovarian Neoplasms 21Myelodysplastic Syndromes 21Triple Negative Breast Neoplasms 20Lymphoma 20Leukemia, Lymphocytic, Chronic, B-Cell 20Burkitt Lymphoma 19Lymphoma, Large B-Cell, Diffuse 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Urinary Bladder Neoplasms 16Carcinoma, Hepatocellular 16Squamous Cell Carcinoma of Head and Neck 15Glioblastoma 15Fallopian Tube Neoplasms 14Oropharyngeal Neoplasms 13Glioma 13Endometrial Neoplasms 13Sarcoma 12Mouth Neoplasms 12Lymphoma, Non-Hodgkin 12

Interventions

luprolide acetate gel depot 1exemestane 1darolutamide 1X-Rays 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Granulosa cell tumor of the ovary × Specimen Handling × 90 days × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡